Astria Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Jonathan Violin, a director of Astria Therapeutics, Inc., reported the disposition of all his common stock and stock options following the company's merger with BioCryst Pharmaceuticals, Inc.
Astria Therapeutics' Chief Medical Officer, Christopher Morabito, received cash for his in-the-money stock options following the company's merger with BioCryst Pharmaceuticals.
Astria Therapeutics CEO Jill C. Milne reports changes in beneficial ownership following the company's merger with BioCryst Pharmaceuticals, Inc.
Astria Therapeutics' Chief Business Officer, Andrea Matthews, received a significant cash payout for her in-the-money stock options following the company's merger with BioCryst Pharmaceuticals.
Astria Therapeutics Director Anthony Gregg Lapointe reported the cancellation of in-the-money stock options for cash following the company's merger with BioCryst Pharmaceuticals.
Astria Therapeutics' Chief Commercial Officer, Andrew Komjathy, reported the disposition of all his beneficial holdings in Astria common stock and stock options following the company's merger with BioCryst Pharmaceuticals.
Astria Therapeutics Director Michael Kishbauch's stock options were canceled and cashed out or forfeited following the company's merger with BioCryst Pharmaceuticals.
Astria Therapeutics' Chief Legal Officer, Benjamin Harshbarger, received over $2 million in cash for his in-the-money stock options following the company's merger with BioCryst Pharmaceuticals.
Astria Therapeutics director Hugh M. Cole reported the cancellation of stock options following the company's merger with BioCryst Pharmaceuticals, Inc.
Astria Therapeutics' Chief Financial Officer, Noah Clauser, disposed of stock options for cash following the company's merger with BioCryst Pharmaceuticals.
Astria Therapeutics Director Fred Callori received cash for in-the-money stock options following the company's merger with BioCryst Pharmaceuticals' subsidiary.
Astria Therapeutics director Joanne Beck's stock options were canceled for cash or no consideration following the company's merger with BioCryst Pharmaceuticals' subsidiary.
Astria Therapeutics director Kenneth Bate received cash for in-the-money stock options following the company's merger with BioCryst Pharmaceuticals, Inc.
Astria Therapeutics Director Sunil Agarwal cashed out all in-the-money stock options following the company's merger with BioCryst Pharmaceuticals' subsidiary.
Astria Therapeutics, Inc. disclosed two lawsuits challenging its proposed merger with BioCryst Pharmaceuticals, Inc., alleging misleading registration statements.
BioCryst Pharmaceuticals announced early termination of the HSR waiting period, moving its acquisition of Astria Therapeutics closer to a Q1 2026 close.
BioCryst Pharmaceuticals announces the acquisition of Astria Therapeutics, adding late-stage HAE compound navenibart to its pipeline and projecting significant revenue growth.
BioCryst Pharmaceuticals announces a proposed merger to acquire Astria Therapeutics, aiming to combine operations and leverage anticipated synergies.
Astria Therapeutics announced an agreement to be acquired by BioCryst Pharmaceuticals for an implied value of $13 per share in a combination of cash and BioCryst stock.
BioCryst Pharmaceuticals, Inc. announced its intent to acquire Astria Therapeutics, Inc., a move communicated to employees on October 14, 2025.
BioCryst Pharmaceuticals will acquire Astria Therapeutics for approximately $920 million in equity value, adding late-stage HAE therapy navenibart and strengthening its rare disease pipeline.
BioCryst Pharmaceuticals will acquire Astria Therapeutics for $920 million, adding late-stage HAE therapy navenibart and strengthening its rare disease pipeline.
Astria Therapeutics, Inc. director Sunil Agarwal was granted 26,550 stock options with an exercise price of $5.79, which will vest on June 11, 2026.
Astria Therapeutics, Inc. Director Kenneth Bate was granted 26,550 stock options with an exercise price of $5.79 per share, aligning his interests with shareholder value.
Astria Therapeutics, Inc. director Hugh M. Cole was granted 26,550 stock options with an exercise price of $5.79, vesting on the one-year anniversary of the grant date.
Astria Therapeutics, Inc. Director Michael D. Kishbauch has been granted 26,550 stock options with an exercise price of $5.79, vesting over one year.
Astria Therapeutics, Inc. director Anthony Gregg Lapointe was granted 26,550 stock options with an exercise price of $5.79, vesting over one year.
Astria Therapeutics, Inc. Director Jonathan Violin was granted 26,550 stock options with an exercise price of $5.79, vesting on June 11, 2026.
Astria Therapeutics, Inc. director Joanne T. Beck was granted 26,550 stock options with an exercise price of $5.79, vesting on the one-year anniversary of the grant date.
Astria Therapeutics, Inc. Director Fred Callori was granted 26,550 stock options with an exercise price of $5.79, vesting in one year.